|Dr. Sharon Mates||Co-Founder, Chairman, CEO & Pres||1.52M||189.42k||1953|
|Mr. Lawrence J. Hineline CPA, CPA||Sr. VP of Fin., CFO, Treasurer & Assistant Sec.||693.55k||336.9k||1956|
|Mr. Michael I. Halstead J.D.||Exec. VP, Gen. Counsel & Sec.||837.47k||N/A||1973|
|Mr. Mark Neumann||EVP & Chief Commercial Officer||914.35k||N/A||1963|
|Dr. Robert E. Davis||Sr. VP & Chief Scientific Officer||N/A||N/A||1951|
|Mr. Juan Fernando Sanchez||VP of Corp. Communications & Investor Relations||N/A||N/A||1971|
|Ms. Karen Patruno Sheehy Esq.||Sr. VP & Chief Compliance Officer||N/A||N/A||1962|
|Dr. Suresh K. Durgam M.D.||Sr. VP & Chief Medical Officer||N/A||N/A||N/A|
|Dr. Michael Olchaskey||Sr. VP & Head of Regulatory Affairs||N/A||N/A||N/A|
|Mr. John A. Bardi||Sr. VP of Market Access, Policy & Gov. Affairs||N/A||N/A||N/A|
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also developing lumateperone, which is in Phase 3 clinical trials for the treatment of bipolar depression, as well as to treat autism spectrum disorder, and sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for the treatment of Parkinson's disease and heart failure; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.
Intra-Cellular Therapies, Inc.’s ISS Governance QualityScore as of April 1, 2021 is 6. The pillar scores are Audit: 7; Board: 5; Shareholder Rights: 7; Compensation: 6.